Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Alkermes plc (ALKS) announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference, with management scheduled for a fireside chat presentation on June 9, 2025, at 10:00 a.m. EDT. The presentation will be accessible via webcast on the company's website under the Investors tab and will remain archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia, with operations across Ireland, Massachusetts, and Ohio.
Alkermes plc (ALKS) ha annunciato la sua partecipazione alla 46ª Conferenza Globale Annuale sulla Sanità di Goldman Sachs, con una presentazione in stile fireside chat prevista per il 9 giugno 2025 alle 10:00 EDT. La presentazione sarà disponibile in webcast sul sito web della società nella sezione Investitori e resterà archiviata per 14 giorni. Alkermes è un'azienda biofarmaceutica globale specializzata in neuroscienze, con prodotti commerciali rivolti alla dipendenza da alcol, dipendenza da oppioidi, schizofrenia e disturbo bipolare I. L'azienda dispone di un portafoglio di candidati clinici e preclinici per disturbi neurologici, tra cui narcolessia e ipersonnia idiopatica, con sedi operative in Irlanda, Massachusetts e Ohio.
Alkermes plc (ALKS) anunció su participación en la 46ª Conferencia Anual Global de Salud de Goldman Sachs, con una presentación tipo charla junto a la chimenea programada para el 9 de junio de 2025 a las 10:00 a.m. EDT. La presentación estará disponible vía webcast en el sitio web de la compañía bajo la pestaña de Inversores y permanecerá archivada durante 14 días. Alkermes es una empresa biofarmacéutica global enfocada en neurociencia, con productos comerciales dirigidos a la dependencia del alcohol, dependencia de opioides, esquizofrenia y trastorno bipolar I. La compañía mantiene una cartera de candidatos clínicos y preclínicos para trastornos neurológicos, incluyendo narcolepsia e hipersomnia idiopática, con operaciones en Irlanda, Massachusetts y Ohio.
Alkermes plc (ALKS)는 2025년 6월 9일 오전 10시(동부 표준시)에 예정된 Goldman Sachs 제46회 연례 글로벌 헬스케어 컨퍼런스에서의 파이어사이드 채팅 발표 참여를 발표했습니다. 발표는 회사 웹사이트의 투자자 탭에서 웹캐스트로 시청 가능하며 14일간 아카이브로 보관됩니다. Alkermes는 신경과학에 중점을 둔 글로벌 바이오제약 회사로, 알코올 의존증, 아편유사제 의존증, 조현병, 양극성 장애 I형을 대상으로 하는 상업용 제품을 보유하고 있습니다. 회사는 기면증 및 특발성 과다수면증을 포함한 신경학적 질환에 대한 임상 및 전임상 후보물질 파이프라인을 유지하고 있으며, 아일랜드, 매사추세츠, 오하이오에 운영 거점을 두고 있습니다.
Alkermes plc (ALKS) a annoncé sa participation à la 46e conférence annuelle mondiale sur la santé de Goldman Sachs, avec une présentation en format discussion prévue le 9 juin 2025 à 10h00 EDT. La présentation sera accessible en webcast sur le site internet de la société dans la section Investisseurs et restera disponible en archive pendant 14 jours. Alkermes est une entreprise biopharmaceutique mondiale spécialisée en neurosciences, avec des produits commerciaux ciblant la dépendance à l'alcool, la dépendance aux opioïdes, la schizophrénie et le trouble bipolaire de type I. L'entreprise dispose d'un portefeuille de candidats cliniques et précliniques pour les troubles neurologiques, notamment la narcolepsie et l'hypersomnie idiopathique, avec des opérations en Irlande, dans le Massachusetts et dans l'Ohio.
Alkermes plc (ALKS) gab seine Teilnahme an der 46. jährlichen globalen Gesundheitskonferenz von Goldman Sachs bekannt, mit einer für den 9. Juni 2025 um 10:00 Uhr EDT geplanten Fireside-Chat-Präsentation des Managements. Die Präsentation wird per Webcast auf der Unternehmenswebsite unter dem Bereich Investoren zugänglich sein und für 14 Tage archiviert bleiben. Alkermes ist ein globales biopharmazeutisches Unternehmen mit Schwerpunkt auf Neurowissenschaften und vertreibt kommerzielle Produkte zur Behandlung von Alkoholabhängigkeit, Opioidabhängigkeit, Schizophrenie und bipolarer Störung Typ I. Das Unternehmen verfügt über eine Pipeline klinischer und präklinischer Kandidaten für neurologische Erkrankungen wie Narkolepsie und idiopathische Hypersomnie und ist in Irland, Massachusetts und Ohio tätig.
Positive
- None.
Negative
- None.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-46th-annual-goldman-sachs-global-healthcare-conference-302471011.html
SOURCE Alkermes plc
FAQ
When is Alkermes (ALKS) presenting at the Goldman Sachs Healthcare Conference 2025?
Alkermes will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025, at 10:00 a.m. EDT (3:00 p.m. BST).
What products does Alkermes (ALKS) currently have in their portfolio?
Alkermes has commercial products for treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder.
What areas is Alkermes (ALKS) developing new treatments for?
Alkermes is developing clinical and preclinical candidates for neurological disorders, specifically including narcolepsy and idiopathic hypersomnia.
Where are Alkermes' (ALKS) main operational locations?
Alkermes is headquartered in Ireland, with a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
How long will the webcast of Alkermes' (ALKS) presentation be available?
The webcast will be archived and available for 14 days on Alkermes' website under the Investors tab.
Alkermes Plc
NASDAQ:ALKS
ALKS Rankings
ALKS Latest News
ALKS Stock Data
4.93B
161.50M
1.45%
106.03%
8.61%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Ireland
DUBLIN 4